Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
61
resultados
Última actualización
14/08/2025 [07:28:00]
Resultados 50 a 61 de 61
Resumen de: KR20250094345A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 판테테이나제(Pantetheinase) 단백질의 발현 수준이 48배 높게 나타나는 것을 확인함에 따라 판테테이나제(Pantetheinase) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094344A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 호르네린(Hornerin) 단백질의 발현 수준이 98배 높게 나타나는 것을 확인함에 따라 호르네린(Hornerin) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: AU2023406056A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: PH12021552938A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2024052650A1
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: WO2025123398A1
An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.
Resumen de: WO2025123283A1
The use of a reagent, which detects changes in the concentration or number of immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid, in the preparation of a diagnostic tool or a therapeutic tool for diagnosing or monitoring Alzheimer's disease. A method for diagnosing or monitoring Alzheimer's disease, in which a reagent for detecting immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid is used to detect changes in the concentration or number of the immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid. A method for treating Alzheimer's disease, in which immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid are taken as targets for administration so as to reduce or decrease the concentration or number of the immune cells and immune factors.
Resumen de: WO2025125705A1
An in vitro procedure for diagnosing or determining the risk of a person developing Alzheimer's disease (AD), said procedure detecting and quantifying the expression products of the LMNA gene (SEQ. ID: No. 3): lamin A protein (SEQ. ID: No. 1) and its precursor prelamin A (SEQ. ID: No. 2), in a sample of peripheral nerve or smooth muscle.
Resumen de: WO2025128726A1
Disclosed herein are methods for analyzing oligomeric protein structures by mass spectrometry. The method includes providing a sample having one or more oligomers; producing, with an ion source, ions of the sample, each of the ions having a mass-to-charge (m z) ratio; detecting a multiplicity of ions generated with a current detector; determining ion masses for each of the multiplicity of ions detected with the current detector with a mass analyzer; generating a mass-domain spectrum from the ion masses with the mass-analyzer, the mass-domain spectrum having one or more mass-domain peaks; and determining one or more metrics capturing the mass heterogeneity and/or mass abundance of oligomers. Methods for diagnosing a subject, assessing treatment efficacy, and assessing treatment efficacy are also provided.
Resumen de: EP4570823A1
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.
Nº publicación: EP4571315A1 18/06/2025
Solicitante:
SHEN ZHEN WISDOM BIOPHARM CO LTD [CN]
Shen Zhen Wisdom Biopharm Co., Ltd
Resumen de: EP4571315A1
A use of a new highly toxic amyloid oligomer Apo*3F as a target for diagnosing Alzheimer's disease (AD) in the early stage and the middle-late stage and mild cognitive impairment (MCI) caused by AD. The Aβo*3F specifically binds to an antibody 3F and is present in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and patients with MCI caused by AD, and the levels show highly significant differences in CSF, blood and/or brain tissue of AD patients, MCI patients and healthy elderly persons. In addition, the Apo*3F is an ultra-highly toxic oligomer, is the most important toxic component in an Aβ oligomer mixture, has a strong pathogenic effect, and plays a key role in the occurrence and development of AD.
BOPI
Sede Electrónica
